Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Paul Johns
Trade Marks

Handok to Commercialise Biocon’s Liraglutide in South Korea

May 22, 2024

Biocon Limited announced on 24 May 2024 that it signed an exclusive licensing and supply agreement with Korea’s Handok Inc for the commercialisation in South Korea of its synthetic liraglutide, biosimilar to Novo Nordisk’s Victoza®.

Under the terms of the agreement, Biocon will be responsible for the development, manufacturing and supply of the drug product, and Handok will manage regulatory approvals and commercialisation in the South Korean market.

Biocon’s liraglutide became the first approved biosimilar to Novo Nordisk’s Victoza® in the UK in March 2024.